

Giuseppe Vita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4887417/publications.pdf>

Version: 2024-02-01

162
papers

8,685
citations

70961

41
h-index

49773

87
g-index

167
all docs

167
docs citations

167
times ranked

10034
citing authors

#	ARTICLE	IF	CITATIONS
1	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. <i>New England Journal of Medicine</i> , 2018, 379, 11-21.	13.9	1,944
2	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. <i>New England Journal of Medicine</i> , 2018, 379, 22-31.	13.9	1,000
3	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1489-1498.	6.3	365
4	Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 320-328.	4.9	222
5	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. <i>Journal of Neuro-Oncology</i> , 2009, 93, 325-332.	1.4	211
6	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2010, 20, 712-716.	0.3	171
7	Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. <i>Sleep Medicine</i> , 2009, 10, 1132-1138.	0.8	152
8	Histological effects of givinostat in boys with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2016, 26, 643-649.	0.3	144
9	Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. <i>Experimental Neurology</i> , 2006, 198, 234-241.	2.0	128
10	Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. <i>Nature Medicine</i> , 2014, 20, 992-1000.	15.2	113
11	Lipid Peroxidation Inhibition Blunts Nuclear Factor- κ B Activation, Reduces Skeletal Muscle Degeneration, and Enhances Muscle Function in mdx Mice. <i>American Journal of Pathology</i> , 2006, 168, 918-926.	1.9	105
12	Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. <i>Skeletal Radiology</i> , 2012, 41, 955-961.	1.2	105
13	Uremic autonomic neuropathy studied by spectral analysis of heart rate. <i>Kidney International</i> , 1999, 56, 232-237.	2.6	104
14	VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. <i>FASEB Journal</i> , 2007, 21, 3737-3746.	0.2	95
15	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 513-522.	4.9	95
16	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. <i>Lancet Neurology</i> , The, 2021, 20, 49-59.	4.9	93
17	Ictal and interictal EEG abnormalities in ADHD children recorded over night by video-polysomnography. <i>Epilepsy Research</i> , 2007, 75, 130-137.	0.8	90
18	Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. <i>Journal of the Neurological Sciences</i> , 1993, 120, 82-86.	0.3	87

#	ARTICLE	IF	CITATIONS
19	Role of Gabapentin in Spinal Muscular Atrophy. <i>Journal of Child Neurology</i> , 2003, 18, 537-541.	0.7	86
20	Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. <i>Annals of Neurology</i> , 2019, 86, 443-451.	2.8	83
21	Motor function-muscle strength relationship in spinal muscular atrophy. <i>Muscle and Nerve</i> , 2004, 29, 548-552.	1.0	81
22	Importance of <i>SPP1</i> genotype as a covariate in clinical trials in Duchenne muscular dystrophy. <i>Neurology</i> , 2012, 79, 159-162.	1.5	81
23	Nuclear factor- κ B activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. <i>Cancer</i> , 2008, 112, 2258-2266.	2.0	70
24	Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S39-S48.	1.1	67
25	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. <i>Neuromuscular Disorders</i> , 2018, 28, 582-585.	0.3	67
26	Cardiovascular-Reflex Testing and Single-Fiber Electromyography in Botulism. <i>Archives of Neurology</i> , 1987, 44, 202.	4.9	65
27	The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1307-1315.	0.5	64
28	Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone. <i>Experimental Neurology</i> , 2009, 220, 349-358.	2.0	58
29	MRI of Cardiac Involvement in Transthyretin Familial Amyloid Polyneuropathy. <i>American Journal of Roentgenology</i> , 2010, 195, W394-W399.	1.0	58
30	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. <i>PLoS ONE</i> , 2015, 10, e0141240.	1.1	58
31	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. <i>Contemporary Clinical Trials</i> , 2017, 58, 34-39.	0.8	56
32	Endocardial and Epicardial Deformations in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. <i>Circulation Journal</i> , 2011, 75, 1200-1208.	0.7	54
33	RAGE-NF- κ B pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 115-121.	1.0	53
34	Reduced Adult Neurogenesis and Altered Emotional Behaviors in Autoimmune-Prone B-Cell Activating Factor Transgenic Mice. <i>Biological Psychiatry</i> , 2010, 67, 558-566.	0.7	52
35	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 259-265.	1.4	51
36	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. <i>Frontiers in Genetics</i> , 2020, 11, 131.	1.1	49

#	ARTICLE	IF	CITATIONS
37	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. <i>Pharmacological Research</i> , 2006, 54, 436-441.	3.1	47
38	Cardiovascular autonomic control in Becker muscular dystrophy. <i>Journal of the Neurological Sciences</i> , 2001, 186, 45-49.	0.3	46
39	Oxidative stress in myotonic dystrophy type 1. <i>Free Radical Research</i> , 2005, 39, 771-776.	1.5	45
40	Expression of muscle-specific integrins in masseter muscle fibers during malocclusion disease. <i>International Journal of Molecular Medicine</i> , 2012, 30, 235-242.	1.8	44
41	Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). <i>Neuromuscular Disorders</i> , 2012, 22, 325-330.	0.3	44
42	Increase in Synchronization of Autonomic Rhythms between Individuals When Listening to Music. <i>Frontiers in Physiology</i> , 2017, 8, 785.	1.3	43
43	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1456.	3.8	43
44	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. <i>Neuromuscular Disorders</i> , 2017, 27, 447-451.	0.3	42
45	Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 385-390.	1.4	41
46	MuSK-Associated Myasthenia Gravis: Clinical Features and Management. <i>Frontiers in Neurology</i> , 2020, 11, 660.	1.1	41
47	Uraemic autonomic neuropathy. <i>Journal of the Autonomic Nervous System</i> , 1990, 30, S179-S184.	1.9	39
48	Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases. <i>Neuromuscular Disorders</i> , 2002, 12, 964-969.	0.3	39
49	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. <i>European Journal of Human Genetics</i> , 2013, 21, 630-636.	1.4	39
50	Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience. <i>Neuromuscular Disorders</i> , 2017, 27, 1084-1086.	0.3	38
51	Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association. <i>Neuromuscular Disorders</i> , 2002, 12, 566-568.	0.3	37
52	Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A. <i>Journal of the Peripheral Nervous System</i> , 2008, 13, 64-70.	1.4	37
53	“œl have got something positive out of this situation” psychological benefits of caregiving in relatives of young people with muscular dystrophy. <i>Journal of Neurology</i> , 2014, 261, 188-195.	1.8	37
54	Hippo signaling pathway is altered in Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2018, 13, e0205514.	1.1	37

#	ARTICLE	IF	CITATIONS
55	Why do some Friedreich's ataxia patients retain tendon reflexes?. <i>Journal of Neurology</i> , 1999, 246, 353-357.	1.8	36
56	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. <i>Neuromuscular Disorders</i> , 2009, 19, 223-228.	0.3	36
57	Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation of the nuclear factor- κ B antiapoptotic activity in human gliomas. <i>Journal of Neurosurgery</i> , 2005, 103, 873-881.	0.9	35
58	Burden, professional support, and social network in families of children and young adults with muscular dystrophies. <i>Muscle and Nerve</i> , 2015, 52, 13-21.	1.0	35
59	Practical approach to respiratory emergencies in neurological diseases. <i>Neurological Sciences</i> , 2020, 41, 497-508.	0.9	33
60	Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred. , 1996, 19, 1134-1137.		32
61	Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findings. <i>Neurological Sciences</i> , 2008, 29, 193-194.	0.9	32
62	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. <i>Neuromuscular Disorders</i> , 2016, 26, 189-196.	0.3	32
63	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. <i>Neurological Sciences</i> , 2019, 40, 661-669.	0.9	32
64	Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. <i>Neuromuscular Disorders</i> , 2005, 15, 409-411.	0.3	31
65	Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. <i>Neurobiology of Aging</i> , 2011, 32, 2190-2197.	1.5	31
66	The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF- α activation and ameliorates muscle function and morphology in mdx mice. <i>Neuromuscular Disorders</i> , 2011, 21, 579-589.	0.3	31
67	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 176.	1.2	31
68	Cardiovascular autonomic control in myotonic dystrophy type 1: a correlative study with clinical and genetic data. <i>Neuromuscular Disorders</i> , 2004, 14, 136-141.	0.3	30
69	Expanding the spectrum of genes responsible for hereditary motor neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1171-1179.	0.9	30
70	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. <i>Journal of Medical Genetics</i> , 2019, 56, 293-300.	1.5	30
71	Extra-muscle involvement in dystrophinopathies: an electroretinography and evoked potential study. <i>Journal of the Neurological Sciences</i> , 1997, 146, 127-132.	0.3	27
72	Apoptosis in metabolic myopathies. <i>NeuroReport</i> , 1998, 9, 2431-2435.	0.6	26

#	ARTICLE	IF	CITATIONS
73	Auditory system involvement in late onset Pompe disease: A study of 20 Italian patients. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 480-484.	0.5	26
74	Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation. <i>American Journal of Cardiology</i> , 2015, 116, 1122-1127.	0.7	26
75	Expression of cytoskeleton proteins in central core disease. <i>Journal of the Neurological Sciences</i> , 1994, 124, 71-76.	0.3	25
76	Autonomic function in elderly uremics studied by spectral analysis of heart rate. <i>Kidney International</i> , 2005, 67, 1521-1525.	2.6	25
77	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. <i>Neuromuscular Disorders</i> , 2014, 24, 1003-1017.	0.3	25
78	An observational study of functional abilities in infants, children, and adults with type 1 SMA. <i>Neurology</i> , 2018, 91, e696-e703.	1.5	24
79	hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers. <i>Brain Sciences</i> , 2020, 10, 780.	1.1	24
80	Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. <i>Acta Myologica</i> , 2014, 33, 136-43.	1.5	24
81	Autonomic dysfunction in uremia. <i>American Journal of Kidney Diseases</i> , 2001, 38, S118-S121.	2.1	22
82	Left atrial function in cardiac amyloidosis. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 113-121.	0.6	21
83	Fetus-like dystrophin expression and other cytoskeletal protein abnormalities in centronuclear myopathies. <i>Muscle and Nerve</i> , 1994, 17, 1176-1184.	1.0	20
84	Endocrine Evaluation for Muscle Pain. <i>Journal of the Royal Society of Medicine</i> , 2001, 94, 405-407.	1.1	20
85	Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. <i>Neuromuscular Disorders</i> , 2009, 19, 44-48.	0.3	20
86	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. <i>Neurological Sciences</i> , 2019, 40, 671-681.	0.9	20
87	Immunolocalization and Activation of Transcription Factor Nuclear Factor κ B in Dysimmune Neuropathies and Familial Amyloidotic Polyneuropathy. <i>Archives of Neurology</i> , 2004, 61, 1097-102.	4.9	19
88	Axial myopathy in myasthenia: A misleading cause of dropped head. <i>Muscle and Nerve</i> , 2004, 29, 329-330.	1.0	19
89	Charcot-Marie-Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family. <i>Neurological Sciences</i> , 2015, 36, 1003-1006.	0.9	18
90	Quantitative Comparison Between Amyloid Deposition Detected by ^{99m}Tc -Diphosphonate Imaging and Myocardial Deformation Evaluated by Strain Echocardiography in Transthyretin-Related Cardiac Amyloidosis. <i>Circulation Journal</i> , 2016, 80, 1998-2003.	0.7	18

#	ARTICLE	IF	CITATIONS
91	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	1.4	18
92	Evidence of cardiovascular autonomic impairment in mitochondrial disorders. Journal of Neurology, 2007, 254, 1498-1503.	1.8	17
93	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	1.1	17
94	Expression of Telomeric Repeat Binding Factor-1 in Astroglial Brain Tumors. Neurosurgery, 2005, 56, 802-810.	0.6	16
95	Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. Neurological Sciences, 2020, 41, 1239-1243.	0.9	16
96	Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia, 2005, 60, 806-810.	1.8	15
97	Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscular Disorders, 2005, 15, 259-261.	0.3	15
98	Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart. Neurological Sciences, 2017, 38, 525-526.	0.9	15
99	Chronic migraine in the first COVID-19 lockdown: the impact of sleep, remote working, and other life/psychological changes. Neurological Sciences, 2021, 42, 4403-4418.	0.9	15
100	Immunocytochemistry of muscle cytoskeletal proteins in acid maltase deficiency. Muscle and Nerve, 1994, 17, 655-661.	1.0	14
101	Immunolocalization and activation of nuclear factor- κ B in the sciatic nerves of rats with experimental autoimmune neuritis. Journal of Neuroimmunology, 2006, 174, 32-38.	1.1	14
102	Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer. Neuromuscular Disorders, 2016, 26, 614-618.	0.3	14
103	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.3	14
104	Muscle uptake of 99m Tc pyrophosphate in patients with neuromuscular disorders. Journal of the Neurological Sciences, 1982, 53, 1-7.	0.3	13
105	Specific matrix metalloproteinase expression in focal myositis: an immunopathological study. Acta Neurologica Scandinavica, 2005, 112, 173-177.	1.0	13
106	Unusual features of central nervous system involvement in <scp>CMTX</scp> associated with a novel mutation of <scp>GJB1</scp> gene. Journal of the Peripheral Nervous System, 2012, 17, 407-411.	1.4	13
107	Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. International Journal of Cardiology, 2013, 168, 4988-4989.	0.8	13
108	Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscular Disorders, 2016, 26, 374-377.	0.3	13

#	ARTICLE	IF	CITATIONS
109	Which are the factors influencing NIV adaptation and tolerance in ALS patients?. <i>Neurological Sciences</i> , 2021, 42, 1023-1029.	0.9	13
110	Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 413-418.	1.1	12
111	Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 102.	1.4	11
112	Comparison of different techniques for detecting 17p12 duplication in CMT1A. <i>Neuromuscular Disorders</i> , 2005, 15, 488-492.	0.3	10
113	Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity. <i>Journal of Muscle Research and Cell Motility</i> , 2006, 27, 83-92.	0.9	10
114	Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. <i>Muscle and Nerve</i> , 2012, 45, 451-452.	1.0	10
115	Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in <i>Mdx</i> mice. <i>BioFactors</i> , 2015, 41, 324-329.	2.6	10
116	Congenital muscular dystrophy: Correlation of muscle biopsy and clinical features. <i>Pediatric Neurology</i> , 1994, 10, 233-236.	1.0	9
117	Quantitation of argyrophilic nucleolar organizer regions in regenerating muscle fibers in Duchenne and Becker muscular dystrophies and polymyositis. <i>Acta Neuropathologica</i> , 1999, 97, 247-252.	3.9	9
118	A family with autosomal dominant mutilating neuropathy not linked to either Charcotâ€œMarieâ€œTooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci. <i>Neuromuscular Disorders</i> , 2002, 12, 286-291.	0.3	9
119	Identification of the infant-type R631C mutation in patients with the benign muscular form of CPT2 deficiency. <i>Neuromuscular Disorders</i> , 2007, 17, 960-963.	0.3	9
120	ANT1 is reduced in sporadic inclusion body myositis. <i>Neurological Sciences</i> , 2013, 34, 217-224.	0.9	9
121	Is it the right time for an infant screening for Duchenne muscular dystrophy?. <i>Neurological Sciences</i> , 2020, 41, 1677-1683.	0.9	9
122	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. <i>Brain Sciences</i> , 2020, 10, 952.	1.1	9
123	A Phase 1/2 Study of Flavocoxid, an Oral NF- κ B Inhibitor, in Duchenne Muscular Dystrophy. <i>Brain Sciences</i> , 2021, 11, 115.	1.1	9
124	Effect of exercise on telomere length and telomere proteins expression in mdx mice. <i>Molecular and Cellular Biochemistry</i> , 2020, 470, 189-197.	1.4	9
125	Psychosocial impact of sport activity in neuromuscular disorders. <i>Neurological Sciences</i> , 2020, 41, 2561-2567.	0.9	8
126	Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. <i>Brain Sciences</i> , 2021, 11, 515.	1.1	8

#	ARTICLE	IF	CITATIONS
127	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 163.	1.2	8
128	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. <i>Cardiology and Therapy</i> , 2021, 10, 481-490.	1.1	8
129	Perineurium talin immunoreactivity decreases in diabetic neuropathy. <i>Journal of the Neurological Sciences</i> , 1997, 146, 7-11.	0.3	7
130	Dp116, talin, vinculin and vimentin immunoreactivities following nerve transection. <i>NeuroReport</i> , 1998, 9, 697-702.	0.6	7
131	Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). <i>Frontiers in Neurology</i> , 2018, 9, 880.	1.1	7
132	Socio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis. <i>Nephro-Urology Monthly</i> , 2015, 7, e27114.	0.0	7
133	Autonomic Involvement in Subacute and Chronic Immune-Mediated Neuropathies. <i>Autoimmune Diseases</i> , 2013, 2013, 1-7.	2.7	6
134	Are novel outcome measures for Charcot-Marie-Tooth disease sensitive to change? The 6-minute walk test and StepWatch Activity Monitor in a 12-month longitudinal study. <i>Neuromuscular Disorders</i> , 2019, 29, 310-316.	0.3	6
135	Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs. <i>Acta Myologica</i> , 2017, 36, 41-45.	1.5	6
136	Letters to the Editor. <i>Muscle and Nerve</i> , 1996, 19, 926-931.	1.0	5
137	Apoptosis and apoptosis-related proteins in thyroid myopathies. <i>Muscle and Nerve</i> , 2002, 26, 383-388.	1.0	5
138	Calpain 3 deficiency in Quail Eater's disease. <i>Annals of Neurology</i> , 2004, 55, 146-147.	2.8	5
139	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 729-731.	0.7	5
140	Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center. <i>Neurological Sciences</i> , 2018, 39, 1961-1964.	0.9	5
141	Early impairment of right ventricular morphology and function in transthyretin-related cardiac amyloidosis. <i>Journal of Cardiovascular Echography</i> , 2021, 31, 17.	0.1	5
142	Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 517-525.	1.8	5
143	Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 197-204.	1.4	5
144	Localization of vinculin and talin at perineurial cells of human sural nerve. <i>NeuroReport</i> , 1995, 6, 2077-2080.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. <i>Journal of the Neurological Sciences</i> , 2006, 246, 31-35.	0.3	4
146	Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies. <i>Acta Neurologica Scandinavica</i> , 2007, 117, 393-398.	1.0	4
147	Novel SHOX Gene Mutation in a Short Boy with Becker Muscular Dystrophy: Double Trouble in Two Adjacent Genes. <i>Hormone Research in Paediatrics</i> , 2008, 69, 124-128.	0.8	4
148	Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions. <i>Acta Myologica</i> , 2017, 36, 19-24.	1.5	4
149	Osteosclerotic Myeloma With Spinal Leptomeningitis and Severe Polyneuropathy. <i>Journal of Computer Assisted Tomography</i> , 2006, 30, 649-652.	0.5	3
150	Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers. <i>Clinical and Translational Imaging</i> , 2017, 5, 545-559.	1.1	3
151	Unilateral hyperhidrosis as persistently isolated feature of syringomyelia and Arnold Chiari type 1. <i>Neurological Sciences</i> , 2018, 39, 1607-1608.	0.9	3
152	From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 279-280.	1.4	3
153	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy. <i>Scientific Reports</i> , 2021, 11, 9216.	1.6	3
154	Have Duchenne Muscular Dystrophy Patients an Increased Cancer Risk?. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 1063-1067.	1.1	3
155	Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance. <i>Acta Myologica</i> , 2020, 39, 191-199.	1.5	3
156	The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 15580.	1.6	2
157	Letter to the editor. <i>Muscle and Nerve</i> , 1995, 18, 251-257.	1.0	1
158	Agenesis of the Internal Carotid Artery Associated with Generalized Epilepsy. <i>Journal of Clinical</i>		